Kristin Brooks, Contract Pharma08.19.20
The U.S. government recently accused two hackers in China of targeting U.S. companies that were conducting COVID-19 research to find treatment and vaccines for COVID-19. The defendants are accused of carrying out a hacking campaign that has targeted companies, NGOs and Chinese dissidents across the globe. Their most recent efforts are believed to be part of a scheme to steal American trade secrets and IP.
These indictments are the latest in a broader campaign to crackdown on the theft of American intellectual property and trade secrets.
Laurie Mims, partner at litigator Keker, Van Nest & Peters focuses part of her practice on trade secret matters, particularly within the biotechnology space, she discusses vulnerabilities within pharma amid hacking efforts and precautions pharmaceutical companies can take to protect their IP. –KB
Laurie Mims, partner at litigator Keker, Van Nest & Peters focuses part of her practice on trade secret matters, particularly within the biotechnology space, she discusses vulnerabilities within pharma amid hacking efforts and precautions pharmaceutical companies can take to protect their IP. –KB
Contract Pharma: Given the high cost of R&D that goes into developing a new vaccine, what threat do hacking schemes pose for pharmaceutical companies in the U.S.? Between competitors?
Continue reading this story and get 24/7 access to Contract Pharma for FREE
FREE SUBSCRIPTION
